Since cluster2 colon cancer cells were also sensitive to BRAF inhibitors and PI3K-mTOR inhibitors treatment, we further identified the association between CDX2 expression and the sensitivity of BRAF inhibitors or PI3K-mTOR inhibitors. Here, CDX2 is linked to colonic neoplasm.